JP6613422B1 - ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 - Google Patents
ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 Download PDFInfo
- Publication number
- JP6613422B1 JP6613422B1 JP2019032144A JP2019032144A JP6613422B1 JP 6613422 B1 JP6613422 B1 JP 6613422B1 JP 2019032144 A JP2019032144 A JP 2019032144A JP 2019032144 A JP2019032144 A JP 2019032144A JP 6613422 B1 JP6613422 B1 JP 6613422B1
- Authority
- JP
- Japan
- Prior art keywords
- ccl11
- royal jelly
- blood
- concentration
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
(2)ローヤルゼリー又はその加工物を有効成分として含有する血中CCL11濃度低減用飲食品組成物。
(3)ローヤルゼリー又はその加工物を有効成分として含有する血中CCL11濃度低減用医薬組成物。
研究協力に同意したBMI 25以上、年齢40歳以上の健常成人男性51名を対象として、二重盲検クロスオーバー試験を行った。使用したローヤルゼリーのカプセル剤の配合処方を表1に、タンパク質及び脂質の量をローヤルゼリーとほぼ同量に合わせたプラセボカプセル剤の配合処方を表2に示す。
・第1期介入:2ヶ月間、ローヤルゼリーのカプセル剤或いはプラセボカプセル剤を、いずれも1日あたり3カプセル摂取させた。
・休薬期間:2ヶ月間
・第2期介入:2ヶ月間、ローヤルゼリーのカプセル剤或いはプラセボのカプセル剤を、ただし各被験者は第1期介入と異なる内容のものを、いずれも1日あたり3カプセル摂取させた。
Claims (3)
- ローヤルゼリー又はその加工物を有効成分とする血中CCL11濃度低減剤。
- ローヤルゼリー又はその加工物を有効成分として含有する血中CCL11濃度低減用飲食品組成物。
- ローヤルゼリー又はその加工物を有効成分として含有する血中CCL11濃度低減用医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019032144A JP6613422B1 (ja) | 2019-02-25 | 2019-02-25 | ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019032144A JP6613422B1 (ja) | 2019-02-25 | 2019-02-25 | ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6613422B1 true JP6613422B1 (ja) | 2019-12-04 |
JP2020130140A JP2020130140A (ja) | 2020-08-31 |
Family
ID=68763364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019032144A Active JP6613422B1 (ja) | 2019-02-25 | 2019-02-25 | ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6613422B1 (ja) |
-
2019
- 2019-02-25 JP JP2019032144A patent/JP6613422B1/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2020130140A (ja) | 2020-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4514333B2 (ja) | 炎症および関節炎に関連する症状を緩和軽減するための天然抗炎症薬としてのバラの実処方物 | |
US5932624A (en) | Vitamin supplement composition | |
CN109222103B (zh) | 增肌组合物和保健食品 | |
US20070218147A1 (en) | Peroxisome Proliferator-Activated Receptor (Ppar) Activator, and Drugs, Supplements, Functional Foods and Food Additives Using the Same | |
TW201304768A (zh) | 使用β-羥基-β-丁酸甲酯促進廢用一段時期後肌肉恢復的方法 | |
US20120183635A1 (en) | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses | |
EP2992933B1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
Ma et al. | Serum lipid-improving effect of soyabean β-conglycinin in hyperlipidaemic menopausal women | |
WO2011163183A2 (en) | Methods for delaying progression of diabetes using salacia oblonga extract | |
JP2021503878A (ja) | 筋肉の質及び/又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法 | |
CN112806580A (zh) | 含有具有脂连蛋白刺激特性的肽组分的营养组合物及其用途 | |
AU2014237101B2 (en) | Nutritional compositions containing a peptide component and uses thereof | |
JP2007070343A (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
JP6613422B1 (ja) | ローヤルゼリー又はその加工物を有効成分とする血中ccl11濃度低減剤 | |
Taslim et al. | Energy regulation in newly diagnosed TB with chronic energy deficiency: free fatty acids and RBP4 | |
CN109045070A (zh) | 一种防治非酒精性脂肪肝病的组合物 | |
JP2007230954A (ja) | 睡眠誘導剤及びストレス性不眠症改善剤 | |
Sratongfaeng et al. | Astaxanthin Supplementation Lowers Dietary Intake in Healthy Subjects. | |
JP6378926B2 (ja) | 血糖値低下用組成物 | |
US20150366938A1 (en) | Nutritional supplement for patients suffering from rheumatic diseases | |
JP2021161070A (ja) | Glp−1分泌促進剤 | |
JP4714438B2 (ja) | 抗疲労剤およびそれを含む飲食品 | |
KR101804296B1 (ko) | 식용피 유래 성분을 포함하는 항암용 조성물 | |
TW202402190A (zh) | 包含源自乳清蛋白的肽的生長促進用組合物 | |
Vahidi et al. | Serum zinc levels in children with growth failure in Kerman province, Iran |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190717 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190806 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190819 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190903 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190926 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6613422 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |